Loratadina ( DrugBank: Loratadina )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
89リンパ脈管筋腫症1

89. リンパ脈管筋腫症


臨床試験数 : 38 薬物数 : 38 - (DrugBank : 15) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 118
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000702-29-ES
(EUCTR)
07/06/202109/02/2021Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM). EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSIS
MedDRA version: 21.0;Level: PT;Classification code 10049459;Term: Lymphangioleiomyomatosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Loratadina STADA 10 mg
Product Name: Loratadina Stada
INN or Proposed INN: LORATADINE
Other descriptive name: LORATADINE
IDIBELL (Institut d’Investigació Biomédica de Bellvitge)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
62Phase 2Spain